COVIDIAB-13: Covid-19 and Diabetes in West of Algeria

Sponsor

Laboratoire De Recherche Sur Le Diabete, Université de Tlemcen (Other)

Overall Status

Unknown status

CT.gov ID

NCT04412746

Collaborator

ATRSS, DGRST, Algeria (Other)

100

Enrollment

Location

Anticipated Duration (Months)

33.8

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

By Jan 7, 2020, Chinese scientists had isolated a novel coronavirus, from patients with virus-infected pneumonia. The WHO designated later this virus as COVID-19 (coronavirus disease 2019). This exponential pandemic coronavirus infection is responsible for severe forms in 15 to 20%, for critical ill requiring ventilation in 5% and for mortality in 2%. Algeria was part of the 13 top priority countries identified by WHO based on their direct links and volume of travel to the infected provinces in China.

It is known that some predisposing conditions lead to a worse outcome with coronavirus.

In China, the overall case-fatality rate was 2.3%, but was higher in patients with diabetes (7.3%). In Italy, the most common comorbidities associated with death from COVID-19 were hypertension (73.8%) and diabetes (33.9%). The US Centers for Disease Control and Prevention suggests diabetes is the most common comorbidity in COVID-19 cases. In the largest cohort NHS England study, death from COVID-19 was strongly associated with uncontrolled diabetes (after full adjustment, HR 2.36).

The West Algerian CORODIAB-13 study aims is (1) to assess the prevalence of diabetes among hospitalized patients with Covid-19, (2) to describe the phenotypic characteristics of patients with diabetes, and (3) to identify the parameters specific to the diabetic which are associated with severe forms.

In the future, this study will provide answers for two main questions

Why diabetics are more at risk of developing Covid-19 infection?
Why diabetics are at high risk of developing severe forms?

Condition or Disease	Intervention/Treatment	Phase
Coronavirus Infections Diabetes Mellitus Prevalence Risk Factors Patient Outcome Assessment Severe Acute Respiratory Syndrome	Drug: MANAGEMENT OF COVID-19

Study Design

Study Type:

Observational

Anticipated Enrollment :

100 participants

Observational Model:

Cohort

Time Perspective:

Prospective

Official Title:

Prevalence of Diabetes Among Hospitalized Patients With Covid-19 in West of Algeria. Identification of Diabetes-related Associated Factors Severe Forms

Actual Study Start Date :

Apr 1, 2020

Anticipated Primary Completion Date :

Jun 30, 2020

Anticipated Study Completion Date :

Jun 30, 2020

Outcome Measures

Primary Outcome Measures

Prevalence of diabetes among all hospitalized COVID-19 [3 months]
Assess the prevalence of diabetes among hospitalized patients with Covid-19 in Area of Tlemcen
Diabetes-related factors risk [3 months]
Describe the clinical and biological characteristics of hospitalized subjects with diabetes and COVID-19

Eligibility Criteria

Criteria

Ages Eligible for Study:

16 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Patients admitted in a hospital center since 1th April 2020
Patients with COVID19 with biological proof (specific PCR) or with clinical and radiological diagnosis.
Patient with diabetes known before the admission
New onset diabetes discovered at admission (plasma glycaemia value strictly greater than 2 g/l at any time)